Leerink Partners Rates REGENXBIO (RGNX) buy, $18 Price Target

Leerink Partners has reaffirmed its buy rating for REGENXBIO Inc., setting a price target of $18, a 80.54% upside from the current price.

By EarningsIQ Research Desk · Published Jun 22, 2026, 10:02 PM EDT · Updated Jun 25, 2026, 2:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Leerink Partners rated REGENXBIO Inc. ($RGNX) "buy" with a $18 price target on June 22, 2026.

Since the rating, $RGNX is up 30.4% after 1 week, up 12.5% after 1 month and down 23.7% to date (from the $9.07 close on Jun 22, 2026).

RGNX REGENXBIO Inc.

$6.92 -49.01% year to date

Daily close · Oct 16, 2026

Key Points

On June 22, 2026, Leerink Partners reiterated its buy rating on REGENXBIO Inc. (NasdaqGS: RGNX) with a price target of $18.
Leerink Partners's $18 price target implies 80.54% upside from REGENXBIO Inc.'s ($RGNX) current $9.97 share price.
The stock is currently priced at $9.97, significantly below its 52-week high of $16.19, suggesting potential for growth.
Analysts have mixed opinions on RGNX, with a mean price target of about $23.73 from 11 analysts.

Get $RGNX trade alerts by text

We text you when insiders, Congress or big funds trade $RGNX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated REGENXBIO Inc. alert may contain errors. Disclosures

Leerink Partners Reiterates Buy Rating

On June 22, 2026, Leerink Partners reiterated its buy rating on REGENXBIO Inc. (NasdaqGS: RGNX) with a price target of $18. This comes as the stock trades at $9.97, well below its 52-week high of $16.19. Mani Foroohar, the analyst behind the rating, notes a positive outlook for the company amidst its ongoing projects.

Analyst rating track record

Leerink Partners vs. the S&P 500

YTD return +41.02% hypothetical

All-time return +41.02% S&P 500 +7.82%

vs. S&P 500 +33.20% ahead of the index

Hypothetical returns from Leerink Partners's disclosed trades, not real profit or advice. How we model this.

How This Call Compares with Wall Street

Leerink’s stance aligns with other recent ratings from Wall Street. On the same day, Baird maintained an outperform rating on RGNX, adjusting its target from $32 to $29. Meanwhile, HC Wainwright & Co. has also maintained a buy rating with a target of $26, reaffirmed just days earlier on June 24. This mixed sentiment highlights diverse expectations for the company’s future performance.

How REGENXBIO Inc. Stock Has Traded

Currently, RGNX shares are trading at $9.97, near its 50-day moving average of $9.91. The stock is significantly below its 52-week high of $16.19, which may signal an opportunity for investors looking for growth. The company has a market cap of about $520.2 million and reported revenue of approximately $174.5 million last year, reflecting a growth of 4.1%.

12-month forecast

$RGNX price target

REGENXBIO Inc. daily closes and this analyst's $18 target. Not advice.

Analysts Set New Price Targets

In addition to Leerink Partners, other firms have recently updated their ratings. Mizuho initiated coverage with an outperform rating and a target of $22 on October 5, while HC Wainwright & Co. maintained a buy rating with a target of $21 as of August 25. The consensus among 11 analysts shows a mean price target of approximately $23.73, indicating a generally positive outlook for the stock despite recent adjustments.

What REGENXBIO Inc. Does

REGENXBIO Inc. is a clinical-stage biotechnology firm based in Rockville, Maryland. The company focuses on gene therapies that deliver functional genes to cells with genetic defects. Its pipeline includes treatments for various diseases, such as RGX-314 for retinal diseases and RGX-202 for Duchenne muscular dystrophy. The reaffirmed buy rating from Leerink Partners suggests confidence in the company's innovative pipeline.

What to Watch at REGENXBIO Inc.

Investors will be looking closely at the upcoming earnings report scheduled for November 5, 2026. This will provide further insights into REGENXBIO's financial health and progress in its clinical trials. Keep in mind that the ratings from analysts reflect views on the company's potential but are based on past performance and may not predict future results.